Alan Bryson, PA
Medical · Laurel, MSNPI 1740675487
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $786 and has fallen 64.3% since, to $281 in 2025.
Across 156 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$436
- Lilly USA, LLC$360
- Amgen$339
- Novo Nordisk$295
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$158
- Abbott$135
- plus $918 from 21 others
What the payments were for
- Food & beverage$2,640100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $436 |
| Lilly USA, LLC | 25 | $360 |
| Amgen | 13 | $339 |
| Novo Nordisk | 18 | $295 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $158 |
| Abbott | 9 | $135 |
| Bayer | 6 | $100 |
| Vanda Pharmaceuticals Inc. | 3 | $97 |
| Averitas Pharma Inc. | 5 | $95 |
| Johnson & Johnson | 4 | $69 |
| Daiichi Sankyo Inc. | 3 | $66 |
| Novartis | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| IBSA Pharma Inc. | 2 | $50 |
| Merck | 3 | $50 |
| AstraZeneca | 3 | $40 |
| Astellas Pharma US Inc | 2 | $38 |
| Shield Therapeutics Inc | 2 | $36 |
| GSK | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Pfizer | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $11 |
How this compares
$2,640 in reported general payments places this provider in the 60th percentile of 65 medical providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 125 | $133,846 |
| JardianceEmpagliflozin | 131 | $122,815 |
| EliquisApixaban | 98 | $87,499 |
| FarxigaDapagliflozin Propanediol | 82 | $68,596 |
| TrulicityDulaglutide | 40 | $41,514 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $40,084 |
| LinzessLinaclotide | 52 | $38,198 |
| MounjaroTirzepatide | 17 | $25,648 |
| MyrbetriqMirabegron | 22 | $21,438 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $18,452 |
| XareltoRivaroxaban | 13 | $16,734 |
| Victoza 2-PakLiraglutide | 27 | $15,299 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $10,334 |
| TradjentaLinagliptin | 11 | $9,519 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $295 | $136,070139 claims |
| Boehringer IngelheimJardiance, Tradjenta | $16 | $132,335142 claims |
| PfizerEliquis | $14 | $87,49998 claims |
| AstraZenecaFarxiga, Symbicort | $40 | $73,75297 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $360 | $67,16257 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $35 | $48,95083 claims |
| AbbVieLinzess, Synthroid | $436 | $40,35078 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $21,43822 claims |
| Johnson & JohnsonXarelto | $69 | $16,73413 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $54 | $5,98813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 65 medical providers in Mississippi.
Other medical in Laurel
- Tiffany KeithLaurel$2K
- Dylan WagnerLaurel$311
- Shannon YoungerColumbus$63K
- Angela DauroBiloxi$25K
- Jenna HabermanFlowood$14K
- Ashley LarsenOcean Springs$11K
- Elise BuckleyClinton$10K
- Caroline BaldwynMadison$9K
- Miranda SudduthMadison$8K
- Catherine DiazFlowood$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.